Market Overview

UPDATE: Stifel Nicolaus Initiates Buy with $72 PT on Mednax; Valuation Attractive

Share:
Related MD
US Stock Futures Edge Lower Ahead Of ADP Report
MEDNAX Announces Acquisition of Pediatric Ear, Nose and Throat Practice in Houston
MEDNAX's (MD) CEO Roger Medel Discusses Q1 2015 Results - Earnings Call Transcript (Seeking Alpha)

Stifel Nicolaus initiates its coverage on Mednax (NYSE: MD) with a Buy rating and a $72 price target.

Stifel Nicolaus comments, "We like the company's prospects for internal growth and acquisitions of neonatology and anesthesiology practices, and view the current valuation, at only the 14th percentile of historical forward P/E, as an attractive entry point. …Our Buy rating is based on an improving internal growth rate, an increasing pace of accretive acquisitions, and a current valuation well below the median (since 2004) forward P/E of 15.1x. The current valuation is at only 14th historical percentile. Our target price of $72, equal to a median multiple applied to our forward EPS estimate, implies 20% price appreciation."

MD closed at $60.01 on Monday.

Latest Ratings for MD

DateFirmActionFromTo
Feb 2015Stifel NicolausUpgradesHoldBuy
Jan 2015Deutsche BankMaintainsBuy
Jan 2015CitigroupMaintainsBuy

View More Analyst Ratings for MD
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Price Target Initiation Pre-Market Outlook Analyst Ratings

 

Related Articles (MD)

Around the Web, We're Loving...